Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer's disease patients. For more information, visit www.acumenpharm.com .

Investors:
Alex Braun
abraun@acumenpharm.com

Media:
AcumenPR@westwicke.com



Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABOS:US
The Conversation (0)

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

  • Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024

  • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024

  • Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027

  • Company to host conference call and webcast today at 8:00 a.m. ET

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.

"In the first quarter, our team remained laser-focused on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced the first patient dosed in this study just last week. We are encouraged by the level of investigator interest in the potential of sabirnetug to offer a best-in-class therapeutic profile for patients, which is a testament to our strong Phase 1 data package and the relationships our team has built with clinical sites," Daniel O'Connell, Chief Executive Officer of Acumen. "We continue to expect to initiate a Phase 1 study with a subcutaneous form of sabirnetug in mid-2024 in an effort to extend the product profile and offer administration optionality for patients. We remain committed to delivering on our strategic priority to advance the clinical development of sabirnetug efficiently and thoughtfully."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.

"Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the forefront of the next generation of Alzheimer's therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug's therapeutic potential and a strong start to the trial."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link . After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Noble Mineral highlights Mann West Nickel Sulphide Initial Resource as announced by Canada Nickel

Noble Mineral highlights Mann West Nickel Sulphide Initial Resource as announced by Canada Nickel

(TheNewswire)

Noble Mineral Exploration Inc.

TORONTO TheNewswire - June 11, 2025 Noble Mineral Exploration Inc. (" Noble " or the " Company ") (TSXV: NOB) (OTCQB: NLPXF) is pleased to announce the initial mineral resource at Mann West as announced by its joint venture partner Canada Nickel in the East Timmins Nickel Company, operating in the Timmins area of Northern Ontario.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Questcorp Mining Forms Advisory Board and Appoints Paul Larkin as Inaugural Advisor

Questcorp Mining Forms Advisory Board and Appoints Paul Larkin as Inaugural Advisor

Questcorp Mining Inc. (CSE: QQQ) (OTCBB: QQCMF) (FSE: D910) ("Questcorp" or the "Company"), an emerging copper and gold exploration company, is pleased to announce the formation of an Advisory Board to support the Company's continued growth and development. The Company is also pleased to announce the appointment of Mr. Paul Larkin, a highly respected industry veteran in the public company sector, as its inaugural advisor.

Saf Dhillon, President and CEO of Questcorp, stated:
"We are thrilled to welcome an accomplished mining executive like Paul Larkin to the Questcorp team. His decision to join as an advisor is a strong endorsement of everything we've built to date. With Paul's experience and guidance, we aim to enhance shareholder value through the advancement of our highly prospective exploration projects in both Canada and Mexico."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Finlay Minerals Announces Closing of Non-Brokered Private Placement of Flow-Through Shares and Non-Flow-Through Units

Finlay Minerals Announces Closing of Non-Brokered Private Placement of Flow-Through Shares and Non-Flow-Through Units

/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/

finlay minerals ltd. (TSXV: FYL) (OTCQB: FYMNF) ("Finlay" or the "Company") is pleased to announce that it has closed its non-brokered private placement (the " Private Placement "), previously announced on May 26, 2025 and June 4, 2025 consisting in the issuance of: (i) 11,206,088 common shares of the Company issued on a flow-through basis under the Income Tax Act ( Canada ) (each, a " FT Share ") at a price of $0.11 per FT Share, and (ii) 4,400,000 non-flow-through units of the Company (each, a " NFT Unit ") at a price of $0.10 per NFT Unit, for aggregate gross proceeds to the Company of $1,672,670 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

Ă—